



# FY 2024 - Preliminary Unaudited Revenue

*SUSTAINABLE INNOVATION, WORLD-CLASS SURGEON EDUCATION,  
AND AN UNWAVERING COMMITMENT TO IMPROVING PATIENT OUTCOMES*

04 February 2025

# Disclaimer

This presentation (the “Presentation”) has been prepared by Medacta Group SA (“Medacta” and together with its subsidiaries, “we”, “us” or the “Group”). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on our website at <https://www.medacta.com/EN/investors>.

## **FORWARD-LOOKING INFORMATION**

This Presentation has been prepared by Medacta and may include forward-looking information and statements concerning the outlook for our business. These statements are based on current expectations, estimates and projections about the factors that may affect our future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as “expects”, “believes”, “estimates”, “targets”, “plans”, “outlook” or similar expressions. There are numerous risks and uncertainties, many of which are beyond

our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this Presentation. The important factors that could cause such differences include: changes in the global economic conditions and the economic

conditions of the regions and markets in which the Group operates; changes in healthcare regulations (in particular with regard to medical devices); the development of our customer base; the competitive environment in which the Group operates; manufacturing or logistics disruptions; the impact of fluctuations in foreign exchange rates; and such other factors as may be discussed from time to time. Although we believe that our expectations reflected in any such forward-looking statement are based upon reasonable assumptions, we can give no assurance that those expectations will be achieved.

## **ALTERNATIVE PERFORMANCE MEASURES**

This Presentation may contain information regarding alternative performance measures. Definitions of these measures and reconciliations between such measures and their IFRS counterparts if not defined in the Presentation may be found on the financial reports available on our website at <https://www.medacta.com/EN/investors>.

THIS PRESENTATION IS NOT AN INVITATION TO PURCHASE SECURITIES OF MEDACTA OR THE GROUP

### **Related Trademarks**

*Medacta Group Related Trademarks are registered at least in Switzerland. The products and services listed below may not be all-inclusive, and other Medacta products and services not listed below may be covered by one or more trademarks. The below products and services may be covered by additional trademarks not listed below. Note that Swiss trademarks may have foreign counterparts.*  
AMIS®, GMK® SpheriKA, MyShoulder®, NextAR™, NextAR™ Spine, MyKA™, MySpine®.

Not all products are available in all countries. Product availability is dependent upon the registration requirements for your country. All trademarks and registered trademarks are the property of their respective owners.

**FRANCESCO SICCARDI**

Chief Executive Officer

**CORRADO FARSETTA**

Chief Financial Officer

# Highlights

*FY 2024 revenue<sup>1</sup> in EUR*

**590.6 m**

*FY 2024 revenue<sup>1</sup> growth*

**16.2 % in cc<sup>2</sup>**

15.6 % in EUR

**Out-of-the-box innovations  
launched in all business lines**

*with aim to improve patient outcome  
and healthcare sustainability*

**Leveraging M.O.R.E Institute  
25th Anniversary World Tour**


*thereby acquiring new surgeons  
across all business line*

**Strengthening team  
177 new employees**

*to further progress in mastering  
challenges, pursue excellence &  
increase network of surgeons*


# Considerable above market revenue growth

**Group revenue CAGR\* (2020-2024):  
18.1%**




- 2024 revenue growth\* of 16.2% yoy
- Revenue CAGR\* (2020-2024) of 18.1%
- Considerable above market revenue growth as result of
  - Out-of-the-box thinking innovations to improve patient outcome and healthcare sustainability
  - Education and personalised training of surgeons
  - Clinical evidence

# Outstanding growth across all geographies




## FY 2024 geographic revenue distribution




- EMEA and NA: outstanding growth rate\* of 16.5%
- APAC: excellent growth rate\* in major markets
- LATAM: growth rate\* in the low twenties

# Clear market outperformance across all business lines




FY 2024 revenue distribution by business line



# Solid growth in Hip

Hip Revenue CAGR\* (2020-2024): 12.8%



## Hip


- Growth mainly attributable to Medacta's Anterior Minimally Invasive Surgery (AMIS) platform
- > 2 times market outperformance 2024E\*\* yoy



**AMIS<sup>®</sup> Experience**  
ANTERIOR MINIMALLY INVASIVE SURGERY  
IN HIP REPLACEMENT

# Notable expansion in Knee

Knee Revenue CAGR\* (2020-2024): 22.1%




## Knee

- Outstanding performance due to Medacta's personalised Kinematic Alignment platform MyKA and GMK SpheriKA
- Robust growth across all geographic regions
- > 3 times market outperformance 2024E\*\* yoy



# Outstanding growth in Spine

Spine Revenue CAGR\* (2020-2024): 17.1%



## Spine

- Solid revenue acceleration strongly supported by Medacta's technologies, particularly by NextAR Spine
- Particularly strong performance in EMEA
- > 3 times market outperformance 2024E\*\* yoy



### Notes

\* in constant currency


\*\* THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT® published by ORTHOWORLD® Inc., published June 2024

Selection of pre-contoured rods



# Continued superior growth in Extremities

Extremities Revenue CAGR\* (2020-2024): 36.5%



## Extremities

- Expansion primarily due to Medacta's Shoulder System, supported by advanced technologies such as MyShoulder and NextAR
- Sportsmed still small, but growing contributor
- > 5 times market outperformance 2024E\*\* yoy in Shoulder and > 7 times in Sportsmed



Notes  
\* in constant currency  
\*\* THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT® published by ORTHOWORLD® Inc., published June 2024

# Key Take-Away Messages

- **Significant above-market FY 2024 revenue<sup>1</sup> growth of 16.2% yoy in constant currency as result of**
  - *Out-of-the-box thinking innovations to improve patient outcome and healthcare sustainability*
  - *Education and personalised training of surgeons*
  - *Further expansion of sales reps and team*



MEDACTA.COM

# Financial Calendar 2025

| Date          | Event                  | Location     |
|---------------|------------------------|--------------|
| 25. March     | Full Year 2024 Results |              |
| 07. May       | AGM                    | Rancate (CH) |
| 31. July      | H1 2025 Revenue        |              |
| 05. September | H1 2025 Results        |              |